Category - Developments

Developments

IntelGenx receives USPTO notice of allowance for loxapine Orange Book eligible patent

The United States Patent and Trademark Office has granted a notice of allowance for IntelGenx’s (TSX:IGX; OTCQB:IGXT) U.S. patent application entitled, “Loxapine Film Oral Dosage Form.” The film formulation patent...

February 21, 2023

Developments

Theralase named to TSXV 2023 Venture 50

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) was named to the TSX Venture Exchange’s 2023 Venture 50, an annual ranking of top-performing companies from five industry sectors. Theralase was recognized in the clean...

February 21, 2023

Developments

Freedom Holding to acquire Maxim Group for $400-million

Freedom Holding (NASDAQ:FRHC), a multi-national financial services firm, agreed to acquire Maxim Group and its registered investment advisory affiliate, Maxim Financial Advisors, for a combination of cash and common...

February 17, 2023

Developments

Aravive to present positive updated data at ASCO GU cancer symposium

Aravive (NASDAQ:ARAV) will present updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU)...

February 14, 2023

Developments

Cardiology imaging study urges use of intravascular imaging for PCI guidance

A new review from the American College of Cardiology’s Interventional Council strongly suggests that intracoronary imaging should now be a routine part of clinical practice, as it can be used to assess the lesion prior...

February 14, 2023

Developments

Cognition completes enrollment in Phase 2 SEQUEL study in AD

Cognition Therapeutics (NASDAQ:CGTX) completed enrollment in the randomized, double-blind Phase 2 SEQUEL study of its CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease. The study was designed to assess...

February 9, 2023

Developments

SeaStar Medical to begin AKI device study to reduce hyperinflammation in adults

The FDA approved SeaStar Medical’s (NASDAQ:ICU) investigational device exemption application to conduct a pivotal study evaluating the effectiveness of its Selective Cytopheretic Device (SCD) in reducing...

February 9, 2023

Developments

Abbott to acquire Cardiovascular Systems for $890-million

Abbott (NYSE:ABT) agreed to acquire Cardiovascular Systems, Inc. (NASDAQ:CSII) for $20 a share or approximately $890-million. Cardiovascular Systems is a leader in devices for atherectomy, a minimally invasive treatment...

February 9, 2023

Developments

IntelGenx in research collaboration with renowned neurologist for Montelukast VersaFilm in PD

IntelGenx (TSX:IGX; OTCQB:IGXT) announced a research collaboration with Per Svenningsson, M.D., Ph.D., of the Karolinska Institute, to plan and conduct a multicentre, randomized, double-blind, placebo-controlled...

February 9, 2023

Developments

NeuroSense cleared in Germany to enroll patients in Phase 2b ALS trial

Germany’s Federal Institute for Drugs and Medical Devices approved NeuroSense Therapeutics’ (NASDAQ:NRSN) clinical trial application to enroll patients in PARADIGM, a Phase 2b study of its lead combination drug...

February 8, 2023

Category - Developments

IntelGenx receives USPTO notice of allowance for loxapine Orange Book eligible patent

Theralase named to TSXV 2023 Venture 50

Freedom Holding to acquire Maxim Group for $400-million

Aravive to present positive updated data at ASCO GU cancer symposium

Cardiology imaging study urges use of intravascular imaging for PCI guidance

Cognition completes enrollment in Phase 2 SEQUEL study in AD

SeaStar Medical to begin AKI device study to reduce hyperinflammation in adults

Abbott to acquire Cardiovascular Systems for $890-million

IntelGenx in research collaboration with renowned neurologist for Montelukast VersaFilm in PD

NeuroSense cleared in Germany to enroll patients in Phase 2b ALS trial

General

More